Buchumschlag

Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia

Relapse of drug-resistant acute lymphoblastic leukemia (ALL) has been associated with increased expression of survivin/BIRC5, an inhibitor of apoptosis protein, suggesting a survival advantage for ALL cells. In the present study, we report that inhibition of survivin in patient-derived ALL can eradi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Park, Eugene (VerfasserIn) , Gang, Eun Ji (VerfasserIn) , Hsieh, Yao-Te (VerfasserIn) , Schaefer, Paul (VerfasserIn) , Chae, Sanna (VerfasserIn) , Klemm, Lars (VerfasserIn) , Huantes, Sandra (VerfasserIn) , Loh, Mignon (VerfasserIn) , Conway, Edward M. (VerfasserIn) , Kang, Eun-Suk (VerfasserIn) , Hoe Koo, Hong (VerfasserIn) , Hofmann, Wolf-Karsten (VerfasserIn) , Heisterkamp, Nora (VerfasserIn) , Pelus, Louis (VerfasserIn) , Keerthivasan, Ganesan (VerfasserIn) , Crispino, John (VerfasserIn) , Kahn, Michael (VerfasserIn) , Müschen, Markus (VerfasserIn) , Kim, Yong-Mi (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: June 28, 2011
In: Blood
Year: 2011, Jahrgang: 118, Heft: 8, Pages: 2191-2199
ISSN:1528-0020
DOI:10.1182/blood-2011-04-351239
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2011-04-351239
Volltext
Verfasserangaben:Eugene Park, Eun Ji Gang, Yao-Te Hsieh, Paul Schaefer, Sanna Chae, Lars Klemm, Sandra Huantes, Mignon Loh, Edward M. Conway, Eun-Suk Kang, Hong Hoe Koo, Wolf-Karsten Hofmann, Nora Heisterkamp, Louis Pelus, Ganesan Keerthivasan, John Crispino, Michael Kahn, Markus Müschen, and Yong-Mi Kim
Beschreibung
Zusammenfassung:Relapse of drug-resistant acute lymphoblastic leukemia (ALL) has been associated with increased expression of survivin/BIRC5, an inhibitor of apoptosis protein, suggesting a survival advantage for ALL cells. In the present study, we report that inhibition of survivin in patient-derived ALL can eradicate leukemia. Targeting survivin with shRNA in combination with chemotherapy resulted in no detectable minimal residual disease in a xenograft model of primary ALL. Similarly, pharmacologic knock-down of survivin using EZN-3042, a novel locked nucleic acid antisense oligonucleotide, in combination with chemotherapy eliminated drug-resistant ALL cells. These findings show the importance of survivin expression in drug resistance and demonstrate that survivin inhibition may represent a powerful approach to overcoming drug resistance and preventing relapse in patients with ALL.
Beschreibung:Gesehen am 09.09.2022
Beschreibung:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2011-04-351239

Ähnliche Einträge